Regression of liver metastases of occult carcinoid tumor with slow release Lanreotide therapy

World Journal of Gastroenterology

Volumn 11, Issue 13, 2005, Pages 2041-2044

  Bondanelli, Marta ^a   Ambrosio, Maria Rosaria ^a   Zatelli, Maria Chiara ^a   Cavazzini, Luigi ^a   Rifa'y, Laura Al Jandali ^a   degli Uberti, Ettore C ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Carcinoid; Somatostatin analogs; Somatostatin receptors

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANGIOPEPTIN; CHROMOGRANIN A; PENTETREOTIDE; SEROTONIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOID; CASE REPORT; CELL PROLIFERATION; FEMALE; HUMAN; IMMUNOREACTIVITY; LIVER METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; OCCULT CANCER; PATIENT SELECTION; SEROTONIN BLOOD LEVEL; SLOW RELEASE FORMULATION; TUMOR REGRESSION; TUMOR VOLUME; URINE LEVEL;

EID: 17144413814     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i13.2041     Document Type: Article

References (28)

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959
2. Rindi G, Capella C, Solcia E. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors. J Mol Med 1998; 76: 413-720
3. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340: 858-868
4. Oberg K. Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 2003; 3: 863-877
5. Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine 2003; 20: 255-264
6. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15 966-973
7. Zatelli MC, Tagliati F, Piccin D, Taylor JE, Culler MD, Bondanelli M, degli Uberti EC. Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 2002; 297: 828-834
8. Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, Schlumberger M, Rougier P. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001; 37: 1014-1019
9. Leong WL, Pasieka JL. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 2002; 79: 180-187
10. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003; 10: 451-458
11. Kulaksiz H, Eissele R, Rossler D, Schulz S, Hollt V, Cetin Y, Arnold R. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumors with subtype specific antibodies. Gut 2002; 50: 52-60
12. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980; 45: 2220-2224
13. Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000; 14: 557-560
14. Rohaizak M, Farndon JR. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours. ANZ J Surg 2002; 72: 635-638
15. Corleto VD, Angeletti S, Schillaci O, Marignani M, Caratozzolo M, Panzuto F, Annibale B, Delle Fave G. Long-term octreotide treatment of metastatic carcinoid tumor. Ann Oncol 2000; 11: 491-493
16. Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Culler MD, degli Uberti EC. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab 2003; 88: 2797-2802
17. Borgstrom P, Hassan M, Wassberg E, Refai E, Jonsson C, Larsson SA, Jacobsson H, Kogner P. The somatostatin analogue octreotide inhibits neuroblastoma growth in vivo. Pediatr Res 1999; 46: 328-332
18. di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N, di Leo A. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996; 77: 402-408
19. Todd JF, Meeran K. The tumor vanishes. Clin Endocrinol 2000; 53: 663-664
20. Imtiaz KE, Monteith P, Khaleeli A. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide. Clin Endocrinol 2000; 53: 755-758
21. Kimura N, Pilichowska M, Date F, Kimura I, Schindler M. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res 1999; 5: 3483-3487
22. Zatelli MC, Piccin D, Bondanelli M, Tagliati F, De Carlo E, Culler MD, Uberti EC. An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro. Horm Metab Res 2003; 35 349-354
23. Arnold R, Wied M, Behr TH. Somatostatin analogs in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother 2002; 3: 643-656
24. Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini JL, Richard B, Dousset B, Bertagna X, Epelbaum J. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 2003; 88: 5353-5360
25. Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997; 8: 1041-1044
26. Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Oberg K. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 1997; 36: 607-614
27. Amarapurkar AD, Davies A, Ramage JK, Stangou AJ, Wight DG, Portmann BC. Proliferation of antigen MIB-1 in metastatic carcinoid tumors removed at liver transplantation: relevance to prognosis. Eur J Gastroenterol Hepatol 2003; 15: 139-143
28. Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumors. Ann Oncol 2001; 12: S69-72